Gainers

• Accuray (NASDAQ:ARAY) shares rose 39.0% to $0.38 during Friday's after-market session. The market value of their outstanding shares is at $33.8 million.
• Sensei Biotherapeutics (NASDAQ:SNSE) shares increased by 14.66% to $23.43. The market value of their outstanding shares is at $26.5 million. The company's, Q1 earnings came out today.
• Sunshine Biopharma (NASDAQ:SBFM) shares rose 10.17% to $0.31. The company's market cap stands at $2.3 million.
• Foghorn Therapeutics (NASDAQ:FHTX) shares increased by 10.05% to $4.17. The company's market cap stands at $237.2 million.
• Equillium (NASDAQ:EQ) stock increased by 7.33% to $2.34. The company's market cap stands at $163.7 million. As per the news, the Q1 earnings report came out 2 days ago.
• OraSure Technologies (NASDAQ:OSUR) stock moved upwards by 6.66% to $3.2. The market value of their outstanding shares is at $203.1 million.

Losers

• First Tracks (NASDAQ:TRAX) shares decreased by 17.2% to $14.0 during Friday's after-market session. The company's market cap stands at $631.0 million.
• P3 Health Partners (NASDAQ:PIII) shares fell 13.29% to $9.79. The company's market cap stands at $13.2 million. The company's, Q1 earnings came out yesterday.
• Lantern Pharma (NASDAQ:LTRN) stock fell 10.6% to $2.81. The market value of their outstanding shares is at $35.0 million. As per the press release, Q1 earnings came out today.
• Cumberland Pharma (NASDAQ:CPIX) stock decreased by 9.51% to $4.95. The company's market cap stands at $73.7 million.
• Quantum Cyber (NASDAQ:QUCY) shares declined by 8.96% to $3.15. The market value of their outstanding shares is at $37.5 million.
• 20/20 Biolabs (NASDAQ:AIDX) stock decreased by 8.09% to $1.25. The company's market cap stands at $14.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.